ZNF281/Zfp281 is a target of miR-1 and counteracts muscle differentiation

Sara Nicolai1, Marco Pieraccioli2, Artem Smirnov2

  • 1Medical Research Council, Toxicology Unit, Department of Pathology, University of Cambridge, UK.

Molecular Oncology
|November 30, 2019
PubMed

Insights

The zinc finger transcription factor ZNF281 is down-regulated during cell differentiation, partly due to miR-1. Its elevated expression in soft tissue sarcomas suggests potential as a prognostic marker.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Aberrant gene and microRNA (miR) expression and impaired differentiation are hallmarks of cancer.
  • The zinc finger transcription factor ZNF281 plays a role in cellular processes, but its function in differentiation and cancer is not fully understood.

Purpose of the Study:

  • To investigate the role of ZNF281 during differentiation across various cell types.
  • To identify microRNAs regulating ZNF281 expression.
  • To assess ZNF281 expression in soft tissue sarcomas and its prognostic significance.

Main Methods:

  • In vitro differentiation assays for epithelial, muscle, and granulocytic cells.
  • Analysis of ZNF281 3'UTR for microRNA binding sites.
  • Expression analysis of ZNF281 in human tumor tissues and normal counterparts.
  • Correlation analysis between ZNF281 expression and patient prognosis.

Main Results:

  • ZNF281 expression decreases during in vitro differentiation and is absent in terminally differentiated tissues.
  • Functional microRNA binding sites in the ZNF281 3'UTR mediate post-transcriptional regulation, including inhibition by miR-1.
  • ZNF281 is significantly overexpressed in rhabdomyosarcoma and leiomyosarcoma compared to normal tissues.
  • Elevated ZNF281 expression in soft tissue sarcomas correlates with a worse prognosis.

Conclusions:

  • ZNF281 plays a role in counteracting muscle differentiation, with its down-regulation mediated partly by miR-1.
  • Tissue-restricted microRNAs may contribute to ZNF281 down-regulation during differentiation.
  • Overexpression of ZNF281 in soft tissue sarcomas indicates its potential as a prognostic biomarker.